<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225341</url>
  </required_header>
  <id_info>
    <org_study_id>HSV-BOT-01-09</org_study_id>
    <nct_id>NCT01225341</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A for Herpes Labialis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo Controlled, Crossover Study to Assess the Safety and Efficacy of Botulinum Toxin A Injections as a Preventative Measure for Herpes Labialis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A&#xD;
      as a preventative measure for Herpes Labialis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too many patients withdrew/lost to follow up&#xD;
  </why_stopped>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Recurrence and Duration of Herpes Labialis Lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Days between last injection and outbreak onset &amp; Days between onset and recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Lesion Size</measure>
    <time_frame>12 months</time_frame>
    <description>Lesions will be measured in millimeters across the maximal lesion length in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment</measure>
    <time_frame>During outbreak</time_frame>
    <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to the Visual Analog Scale for pain (VAS) by placing a straight line intersecting the pain line. The scale will be 10 cm long and the distance from start to mark will be measured in millimeters.&#xD;
Score range is 0-10. Scores closer to 0 signify lower pain levels and scores closer to 10 signify high pain levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Evaluation</measure>
    <time_frame>During outbreak</time_frame>
    <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to a 4-point scale ((0) none, (1) mild, (2) moderate, (3) severe).&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>onabotulinumtoxinA/placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacteriostatic normal saline/ onabotulnimtoxinA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
    <arm_group_label>Bacteriostatic normal saline/ onabotulnimtoxinA</arm_group_label>
    <arm_group_label>onabotulinumtoxinA/placebo</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bacteriostatic normal saline</intervention_name>
    <description>Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
    <arm_group_label>Bacteriostatic normal saline/ onabotulnimtoxinA</arm_group_label>
    <arm_group_label>onabotulinumtoxinA/placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females between the ages of 18 and 64.&#xD;
&#xD;
          -  Have herpes simplex virus 1 (HSV-1) with between 2-6 herpes labialis recurrences per&#xD;
             year.&#xD;
&#xD;
          -  Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Subjects of childbearing potential must have a negative urine pregnancy test result at&#xD;
             Visit 1 and be willing able to use an acceptable method of birth control (e.g.,&#xD;
             barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical&#xD;
             sterilization, abstinence) during the study. Women will not be considered of&#xD;
             childbearing potential if one of the following is documented on the medical history:&#xD;
&#xD;
          -  postmenopausal for at least 12 months prior to study drug administration&#xD;
&#xD;
          -  without a uterus and/or both ovaries&#xD;
&#xD;
          -  has had a bilateral tubal ligation for at least 6 months prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  absence of an other physical condition according to the PI's discretion&#xD;
&#xD;
          -  Willingness and ability to provide written photo consent and adherence to photography&#xD;
             procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent prior to performance of&#xD;
             any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a&#xD;
             reliable form of birth control.&#xD;
&#xD;
          -  Subjects with a known allergy or sensitivity to any component of the study medications&#xD;
             or anesthesia.&#xD;
&#xD;
          -  Active recurrence of herpes labialis.&#xD;
&#xD;
          -  Botulinum toxin to the lower 1/3 of the face with the past 6 months.&#xD;
&#xD;
          -  Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart&#xD;
             failure.&#xD;
&#xD;
          -  Concurrent skin condition affecting area to be treated.&#xD;
&#xD;
          -  Prior surgery on the area to be treated within 3 months of initial treatment or during&#xD;
             the study.&#xD;
&#xD;
          -  History or evidence of keloids or hypertrophic scarring.&#xD;
&#xD;
          -  Current use of antivirals for the treatment of herpes labialis within 2 weeks prior to&#xD;
             initiation of treatment (e.g., acyclovir, valaciclovir, famciclovir, and penciclovir).&#xD;
&#xD;
          -  Topical use of over-the-counter medications for the treatment or prevention of HSV-1&#xD;
             (e.g., Abreva).&#xD;
&#xD;
          -  Subjects currently using aminoglycoside antibiotics, curare-like agents or other&#xD;
             agents that might interfere with neuromuscular function.&#xD;
&#xD;
          -  Subjects with a diagnosis of Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic&#xD;
             Lateral Sclerosis, or any other disease that might interfere with neuromuscular&#xD;
             function or current facial palsy.&#xD;
&#xD;
          -  Current history of chronic drug or alcohol abuse.&#xD;
&#xD;
          -  Concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study medication.&#xD;
&#xD;
          -  Subjects who, in the Investigator's opinion, have a history of poor cooperation,&#xD;
             non-compliance with medical treatment or unreliability.&#xD;
&#xD;
          -  Enrollment in any active study involving the use of investigational devices or drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research/ Chicago Center for Facial Plastic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.denovaresearch.com</url>
    <description>DeNova Research</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 19, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <results_first_submitted>August 11, 2020</results_first_submitted>
  <results_first_submitted_qc>November 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 21, 2020</results_first_posted>
  <last_update_submitted>November 24, 2020</last_update_submitted>
  <last_update_submitted_qc>November 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>DeNova Research</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>HSV-1</keyword>
  <keyword>Herpes labialis</keyword>
  <keyword>Cold sores</keyword>
  <keyword>Fever blisters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>onabotulinumtoxinA/Placebo</title>
          <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.&#xD;
onabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
        <group group_id="P2">
          <title>Bacteriostatic Normal Saline/ onabotulnimtoxinA</title>
          <description>Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.&#xD;
onabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
      <group_list>
        <group group_id="B1">
          <title>onabotulinumtoxinA/Placebo</title>
          <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.&#xD;
onabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
        <group group_id="B2">
          <title>Bacteriostatic Normal Saline/ onabotulnimtoxinA</title>
          <description>Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.&#xD;
onabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Recurrence and Duration of Herpes Labialis Lesions</title>
        <description>Days between last injection and outbreak onset &amp; Days between onset and recurrence</description>
        <time_frame>12 months</time_frame>
        <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA</title>
            <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months.&#xD;
OnabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
          <group group_id="O2">
            <title>Bacteriostatic Normal Saline</title>
            <description>Patients will be injected every 3 months with saline for a period of 12 months.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Recurrence and Duration of Herpes Labialis Lesions</title>
          <description>Days between last injection and outbreak onset &amp; Days between onset and recurrence</description>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days between last injection and and outbreak onset</title>
            </class>
            <class>
              <title>Days between onset and recurrence</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Lesion Size</title>
        <description>Lesions will be measured in millimeters across the maximal lesion length in mm</description>
        <time_frame>12 months</time_frame>
        <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA</title>
            <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months.&#xD;
OnabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
          <group group_id="O2">
            <title>Bacteriostatic Normal Saline</title>
            <description>Patients will be injected every 3 months with saline for a period of 12 months.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Lesion Size</title>
          <description>Lesions will be measured in millimeters across the maximal lesion length in mm</description>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessment</title>
        <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to the Visual Analog Scale for pain (VAS) by placing a straight line intersecting the pain line. The scale will be 10 cm long and the distance from start to mark will be measured in millimeters.&#xD;
Score range is 0-10. Scores closer to 0 signify lower pain levels and scores closer to 10 signify high pain levels</description>
        <time_frame>During outbreak</time_frame>
        <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA</title>
            <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months.&#xD;
OnabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
          <group group_id="O2">
            <title>Bacteriostatic Normal Saline</title>
            <description>Patients will be injected every 3 months with saline for a period of 12 months.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment</title>
          <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to the Visual Analog Scale for pain (VAS) by placing a straight line intersecting the pain line. The scale will be 10 cm long and the distance from start to mark will be measured in millimeters.&#xD;
Score range is 0-10. Scores closer to 0 signify lower pain levels and scores closer to 10 signify high pain levels</description>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Evaluation</title>
        <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to a 4-point scale ((0) none, (1) mild, (2) moderate, (3) severe).&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
        <time_frame>During outbreak</time_frame>
        <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
        <group_list>
          <group group_id="O1">
            <title>OnabotulinumtoxinA</title>
            <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months.&#xD;
OnabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
          <group group_id="O2">
            <title>Bacteriostatic Normal Saline</title>
            <description>Patients will be injected every 3 months with saline for a period of 12 months.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Evaluation</title>
          <description>Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to a 4-point scale ((0) none, (1) mild, (2) moderate, (3) severe).&#xD;
Scores closer to 0 indicate a more favorable outcome.</description>
          <population>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</time_frame>
      <desc>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</desc>
      <group_list>
        <group group_id="E1">
          <title>onabotulinumtoxinA</title>
          <description>Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months.&#xD;
onabotulinumtoxinA: Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
        <group group_id="E2">
          <title>Bacteriostatic Normal Saline</title>
          <description>Patients will be injected every 3 months with saline for a period of 12 months.&#xD;
Bacteriostatic normal saline: Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated and the PI/study team no longer has access to study data as it was destroyed. Efforts were exhausted to locate any remaining data, but were unsuccessful. No study data are available to report</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Dayan, MD</name_or_title>
      <organization>DeNova Research</organization>
      <phone>3123352070</phone>
      <email>sdayan@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

